Rosas-Hostos Infantes Luis Raúl, Paredes Yataco Guillermo Andres, Ortiz-Martínez Yeimer, Mayer Treana, Terashima Angelica, Franco-Paredes Carlos, Gonzalez-Diaz Esteban, Rodriguez-Morales Alfonso J, Bonilla-Aldana D Katterine, Vargas Barahona Lilian, Grimshaw Alyssa A, Chastain Daniel B, Sillau Stefan, Marcos Luis A, Henao-Martínez Andrés F
Facultad de Medicina Alberto Hurtado, Universidad Peruana Cayetano Heredia, Lima, Perú.
Department of Internal Medicine, Universidad Industrial de Santander and Hospital Universitario de Santander, Bucaramanga, Colombia.
Ther Adv Infect Dis. 2023 Jul 8;10:20499361231185413. doi: 10.1177/20499361231185413. eCollection 2023 Jan-Dec.
Fascioliasis is a parasitic zoonosis that can infect humans and be a source of significant morbidity. The World Health Organization lists human fascioliasis as a neglected tropical disease, but the worldwide prevalence of fascioliasis data is unknown.
We aimed to estimate the global prevalence of human fascioliasis.
We performed a systematic review and prevalence meta-analysis. We used the following inclusion criteria: articles published in the English, Portuguese, or Spanish languages from December 1985 to October 2022 and studies assessing the prevalence of in the general population with an appropriate diagnostic methodology, including longitudinal studies, prospective and retrospective cohorts, case series, and randomized clinical trials (RCTs). We excluded animal studies. Two reviewers independently reviewed the selected studies for methodological quality, performing critical standard measures from JBI SUMARI. A random-effects model was conducted of the summary extracted data on the prevalence proportions. We reported the estimates according to the GATHER statement.
In all, 5617 studies were screened for eligibility. Fifty-five studies from 15 countries were selected, including 154,697 patients and 3987 cases. The meta-analysis revealed a pooled prevalence of 4.5% [95% confidence interval (CI): 3.1-6.1; = 99.4%; = 0.07]. The prevalence in South America, Africa, and Asia was 9.0%, 4.8%, and 2.0%, respectively. The highest prevalence was found in Bolivia (21%), Peru (11%), and Egypt (6%). Subgroup analysis showed higher prevalence estimates in children, in studies from South America, and when Fas2-enzyme-linked immunosorbent assay (ELISA) was used as a diagnostic method. A larger study sample size ( = 0.027) and an increase in female percentage ( = 0.043) correlated with a decrease in prevalence. Multiple meta-regression showed a higher prevalence for hyperendemic than hypoendemic ( = 0.002) or mesoendemic ( = 0.013) regions.
The estimated prevalence and projected disease burden of human fascioliasis are high. Study findings support that fascioliasis continues to be a globally neglected tropical disease. Strengthening epidemiological surveillance and implementing measures to control and treat fascioliasis is imperative in the most affected areas.
肝片吸虫病是一种人畜共患寄生虫病,可感染人类并导致严重发病。世界卫生组织将人类肝片吸虫病列为被忽视的热带病,但全球肝片吸虫病的流行数据尚不清楚。
我们旨在估计全球人类肝片吸虫病的流行率。
我们进行了一项系统综述和流行率荟萃分析。我们使用了以下纳入标准:1985年12月至2022年10月以英文、葡萄牙文或西班牙文发表的文章,以及采用适当诊断方法评估普通人群中肝片吸虫病流行率的研究,包括纵向研究、前瞻性和回顾性队列研究、病例系列研究以及随机临床试验(RCT)。我们排除了动物研究。两名评审员独立审查所选研究的方法学质量,采用JBI SUMARI的关键标准措施。对提取的关于流行率比例的汇总数据进行随机效应模型分析。我们根据GATHER声明报告估计值。
总共筛选了5617项研究以确定其是否符合资格。选择了来自15个国家的55项研究,包括154,697名患者和3987例病例。荟萃分析显示合并流行率为4.5%[95%置信区间(CI):3.1 - 6.1;I² = 99.4%;P = 0.07]。南美洲、非洲和亚洲的流行率分别为9.0%、4.8%和2.0%。流行率最高的是玻利维亚(21%)、秘鲁(11%)和埃及(6%)。亚组分析显示,在儿童、来自南美洲的研究以及使用Fas2酶联免疫吸附测定(ELISA)作为诊断方法时,流行率估计值较高。更大的研究样本量(P = 0.027)和女性比例的增加(P = 0.043)与流行率的降低相关。多元meta回归显示,高度流行地区的流行率高于低度流行(P = 0.002)或中度流行(P = 0.013)地区。
估计的人类肝片吸虫病流行率和预计的疾病负担很高。研究结果支持肝片吸虫病仍然是一种全球被忽视的热带病。在受影响最严重的地区,加强流行病学监测并实施控制和治疗肝片吸虫病的措施势在必行。